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in the cerebrospinal fluid of patients 
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Abstract 
Background: The chemokine CXCL13 has been discussed as a diagnostic parameter with high specificity for Lyme 
neuroborreliosis (LNB) and as a marker of disease activity. Neurosyphilis and LNB share similar characteristics. We 
investigated retrospectively CXCL13 levels in the cerebrospinal fluid (CSF) of patients with neurosyphilis at initial diag‑
nosis and during treatment.
Results: Five patients with neurosyphilis were identified retrospectively using an electronic database in a tertiary 
care hospital from 2005 to 2012. CXCL13 levels were measured using an ELISA. Five patients with definite LNB and 10 
patients with multiple sclerosis (MS) served as controls. Median CXCL13 levels at baseline were 972 pg/mL for neu‑
rosyphilis patients, 8,000 pg/mL for LNB patients, and 7.8 pg/mL for MS patients. Patients with LNB and neurosyphilis 
showed significantly higher CXCL13 levels in their CSF compared to MS patients (p < 0.05, p < 0.001, respectively). 
CXCL13 levels in the CSF declined during treatment.
Conclusion: CXCL13 levels in the CSF of patients with neurosyphilis can be as high as in patients with LNB, exceed‑
ing the proposed threshold of 250 pg/mL for the diagnosis of LNB. Patients with encephalitic/myelitic syndromes 
appear to have especially high levels of CXCL13. Clinicians should be aware that high levels of CXCL13 are not found 
exclusively in LNB but also in other infectious diseases of the CNS.
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Background
Syphilis is a sexually transmitted spirochetal disease 
caused by Treponema pallidum subspecies pallidum. 
The incidence of syphilis has been on the rise in west-
ern countries over recent years, and late manifestations 
of the disease occur with an incidence of approximately 
7/100,000 inhabitants in the United States [1]. A more 
frequent occurrence of patients with neurosyphilis is 
to be expected in the coming years [2]. The chemokine 
CXCL13 is produced by antigen-presenting cells and is 
thought to play a role in attracting B cells and B-helper T 
cells into the cerebrospinal fluid (CSF) in neuroinfectious 
diseases [3]. CXCL13 is expressed at high levels in the 
CSF of patients with Lyme neuroborreliosis (LNB) [4–7]. 
The sensitivity and specificity of CXCL13 for the diag-
nosis of LNB are reported to be above 90% [4, 8]. Other 
non-infectious inflammatory diseases of the nervous 
system, like multiple sclerosis (MS), show only slight 
elevations of CXCL13 levels in the CSF [9]. In addition, 
CXCL13 levels in the CSF seem to be a surrogate marker 
for disease activity in LNB as CXCL13 levels correlate 
with pleocytosis and quickly fall after the initiation of 
antibiotic treatment [10, 11]. Despite these compelling 
findings, the specificity of CXCL13 for LNB is a matter 
of controversy, especially when other subacute diseases 
of the nervous system are considered. Elevated levels of 
CXCL13 were also reported for CNS lymphoma, HIV 
infection, cryptococcosis, and neurosyphilis [9, 12–14]. 
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et al. [9] to distinguish between LNB and other diseases. 
However, there is no generally accepted cut-off for diag-
nosing LNB on the basis of CXCL13 levels in CSF. As 
neurosyphilis shares some similarities with LNB (e.g., 
spirochetal origin, subacute course, and similar CSF 
changes), we aimed to measure CXCL13 levels in the 
CSF of patients with clinically and serologically definite 
neurosyphilis before and during antibiotic treatment and 
compared the results with those of patients with definite 
LNB and MS.
Methods
Using an electronic database search in a tertiary 
care university hospital (Albert Ludwigs University 
Freiburg), we retrospectively searched for patients 
with neurosyphilis from 2005 until 2012. Patients with 
definite neurosyphilis were diagnosed according to the 
criteria of the Centers of Disease Control and Preven-
tion and the German Academy of Neurology (Deutsche 
Gesellschaft für Neurologie). Accordingly, they had to 
fulfill all of the following criteria: compatible neurologi-
cal syndrome, CSF pleocytosis [white blood cell (WBC) 
count >5/µL], dysfunction of the blood–CSF barrier 
[elevated albumin CSF–serum quotient (QAlb) and total 
CSF protein], positive Venereal Disease Research Labo-
ratory (VDRL) test in CSF, positive T. pallidum particle 
agglutination assay (TPPA) in serum and CSF, and fluo-
rescent Treponemal antibody-absorption (FTA-ABS) 
test in serum [15, 16]. Patients were excluded if they had 
relevant co-infections that could possibly interfere with 
the measurement of CXCL13 (e.g., HIV) or were treated 
with antibiotics before lumbar puncture. Patients with 
LNB had to fulfill the criteria proposed by Stanek et al. 
[17] and were matched with neurosyphilis patients for 
age and sex. MS patients were diagnosed according to 
the 2010 revised McDonald criteria [18]. They served 
as a “negative” control group and were not matched for 
age and sex. CSF samples were collected at the time of 
diagnosis and during the course of the disease as part 
of the initial diagnostic work-up via lumbar puncture. 
Superfluous CSF material was stored for further investi-
gation at −80°C. CSF samples were stored, treated, and 
analyzed in the same manner for all included patients. 
CXCL13 levels were measured using an ELISA test 
system (Quantikine; R&D Systems, Minneapolis, MN, 
USA) according to the instructions supplied by the 
manufacturer. Details on the application of the assay for 
CSF have previously been published [4]. When follow-
up CSF samples were available for the neurosyphilis 
patients, they were also used to measure CXCL13 in 
order to investigate the role of the chemokine in the 
course of the disease.
The study was approved by the Ethics Committee of 
the University Medical Center Freiburg, and written 
informed consent was obtained from all patients.
For comparisons between multiple groups, the 
Kruskal–Wallis test with Dunn’s post-test was used. For 
comparisons between two groups, the Mann–Whitney 
test was performed. Correlations were investigated with 
Spearman’s rank correlation coefficient. A p value of 
<0.05 was regarded as statistically significant. Statistics 
were performed with Prism 4.0b for Macintosh (Graph-
Pad Software, San Diego, CA, USA).
Results
Using our strict inclusion criteria, five consecutive 
patients with confirmed neurosyphilis were identified. 
The clinical, demographic, and CSF routine laboratory 
characteristics of these patients are shown in Table 1. All 
neurosyphilis patients had late-stage neurosyphilis. The 
clinical syndromes were heterogeneous. Subsequent to 
the first lumbar puncture, patients #1, #3, and #5 were 
treated with 30 Mio IU penicillin G IV for 14 days while 
patient #2 was treated with 24 Mio IU penicillin G IV for 
14 days. Patient #4 was treated with 24 Mio IU penicillin 
G IV for 21 days and received additional treatment with 
corticosteroids to avoid occlusion of the cerebral vessels.
The mean WBC count in the CSF at the baseline level was 
58/µL (SD 68, range 13–192) in patients with neurosyphilis, 
209/µL (SD 138, range 84–427) in patients with LNB, and 5/
µL (SD 4.5, range 1–14) in patients with MS. The mean total 
protein in the CSF at the baseline was 1,154 mg/L (SD 524, 
range 648–2,150) in patients with neurosyphilis, 1,445 mg/L 
(SD 711.7, range 977–2,650) in patients with LNB, and 
491 mg/L (SD 139, range 345–743) in patients with MS.
The median baseline CXCL13 levels in the CSF sam-
ples were 972 pg/mL (IQR 213–6,870, range 134–7,140) 
for patients with neurosyphilis, 8,000 pg/mL (IQR 4,170–
20,747; range 3,247–29,110) for patients with LNB, and 
7.8  pg/mL (IQR 7.8–20.6; range 7.8–59.4) for patients 
with MS. The baseline levels of CXCL13 in patients with 
neurosyphilis showed a high variance, with the highest 
values observed in patient #5 with meningoencephalitis 
(7,140  pg/mL) and in patient #3 with encephalomyelitis 
(6,600 pg/mL).
There was a non-significant trend toward higher base-
line values of CXCL13 in patients with LNB compared 
to neurosyphilis (Figure  1a). However, the difference in 
the mean baseline CXCL13 levels was statistically sig-
nificant for both neurosyphilis and LNB compared to MS 
(Figure 1a, p < 0.05, p < 0.001, respectively). During the 
course of treatment, CXCL13 levels rapidly declined in 
neurosyphilis patients, paralleling the course of WBCs in 
the CSF (Figure 1b).
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Conclusions
This is the first controlled study reporting on CXCL13 
levels in CSF from patients diagnosed with neurosyphi-
lis but without confounding co-infections at the time of 
the first diagnosis and during the course of treatment. 
The presented results stem from a small population, 
therefore, the conclusions are rather limited. It may be 
noted that long periods of storage can lead to decreased 
CXCL13 levels. However, as some of the highest values 
of CXCL13 were estimated in the oldest samples, this 
issue seems unlikely. Schiffer et  al. [19] report no dis-
cernible loss of CXCL13 after repeated cycles of freez-
ing and thawing serum samples. Our main finding is that 
CXCL13 levels are substantially elevated in CSF from 
patients with untreated neurosyphilis and can surge as 
high as previously reported for patients with LNB [13]. 
Furthermore, the CXCL13 baseline values from 80% of 
our patients with neurosyphilis exceed the threshold of 
250  pg/mL for the diagnosis of LNB proposed by van 
Burgel et al. [9]. However, there is no generally accepted 
cut-off for diagnosing LNB on the basis of CXCL13 levels 
in CSF as reported cut-offs range from <100 to more than 
1,000 pg/ml [6, 7]. Whether a general cut-off for diagnos-
ing LNB would be reasonable remains doubtful in the 
context of our finding that the CSF of patients with neu-
rosyphilis can also show high levels of CXCL13. Other 
cytokines, such as neopterin, that are elevated in the CSF 
of LNB patients, but not in patients with other neuroin-
fectious conditions, are also elevated in the CSF of neu-
rosyphilis patients [5]. Our results are in line with Marra 
et al. [20] who report similar CXCL13 levels in the CSF of 
83 patients with HIV and symptomatic or asymptomatic 
Table 1 Clinical and CSF parameters
Clinical, demographic, and CSF routine laboratory characteristics at baseline and CXCL13 levels in CSF at baseline and during follow-up in neurosyphilis patients. 
Venereal disease research laboratory (VDRL) titers >1 are regarded as positive.
WBC white blood cell, QAlb albumin CSF–serum quotient, n.a. not available, ref reference values.













CXCL13 in CSF (pg/mL)  
(Ref.: <10)
Baseline 1 month 3 months
1 79 M Encephalomy‑
elitis
18 878 9.3 2 292.6 66.8 17.7
2 55 F Multiple cranial 
nerve palsies
25 933 12.5 8 134 24 7.8
3 56 M Encephalomy‑
elitis, cranial 
nerve palsies
42 648 6.3 32 6,600 183 n.a.
4 51 M Cerebral  
vasculitis
192 1,160 12.4 32 972 184 n.a.
5 39 M Meningoen‑
cephalitis
13 2,150 17.5 4 7,140 138 10
Figure 1 a CXCL13 levels in CSF at baseline in patients with neuro‑
syphilis (n = 5), neuroborreliosis (n = 5, LNB), and multiple sclerosis 
(n = 10, MS). The box includes all values from the first (25%) to the 
third quartile (75%) while the band inside the box corresponds to the 
median. The ends of the whiskers represent the range. b CXCL13 
levels (left ordinate) and WBC count (right ordinate) in the CSF of neu‑
rosyphilis patients during the course of disease. Circles represent the 
mean, and whiskers represent the standard errors. Correlation with 
Spearman‘s rank correlation: r = 1.00; p = 0.33.
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neurosyphilis. However, HIV may also lead to elevated 
levels of CXCL13 in CSF, so the results of Marra et  al. 
may not solely be due to neurosyphilis [9].
Levels of CXCL13 in the CSF of patients with neu-
rosyphilis declined during antibiotic therapy, in paral-
lel with the clinical improvement of symptoms and a 
decrease in the WBC count in the CSF, thus represent-
ing another marker of CNS inflammation. CXCL13 
levels might be part of the inflammatory response to 
infection of the CNS with T. pallidum and may serve 
as a marker of disease activity in neurosyphilis. Marra 
et al. [20] report declining CXCL13 levels during treat-
ment which is corroborated by our findings. Other 
reports have shown different CXCL13 levels in the CSF 
of patients with neurosyphilis, which were found to be 
remarkably lower than in CSF samples from patients 
with LNB [9, 14, 21]. This difference could be due to 
pre-analytical sampling and handling conditions. Dif-
ferent clinical manifestations of neurosyphilis may 
account for the diverging results. In our study, neuro-
syphilis patients with encephalitic and/or myelitic syn-
dromes (e.g., spastic gait, seizures, or aphasia) showed 
the highest CXCL13 levels in their CSF. Both patients 
with isolated palsies of cranial nerves or cerebral luetic 
vasculitis showed substantially lower CXCL13 levels. 
Unfortunately, Rupprecht et  al. and van Burgel et  al. 
provide no information on the clinical syndromes. 
Marra et al. do not provide details on the clinical mani-
festations of neurosyphilis in their patient population 
but show that CXCL13 levels are higher in patients 
with HIV and neurosyphilis compared to patients with 
HIV and syphilis but without neurological symptoms. 
A possible association between different neurologi-
cal manifestations and CXCL13 levels in CSF should 
be the subject of further prospective investigations in 
neurosyphilis.
In conclusion, as elevated CXCL13 levels are not 
pathognomonic for a single condition, interpretation 
of CSF analysis should only be performed by includ-
ing measurements of antibodies against both Borrelia 
burgdorferi and T. pallidum in CSF. Clinicians should be 
aware that high levels of CXCL13 are not found exclu-
sively in LNB but in various infectious diseases of the 
CNS.
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